Skip to content

Effect of Esketamine on Plasma Bone Morphogenetic Protein-4 in Thoracic Surgery

Clinical study on perioperative application of esketamine to reduce inflammation through BMP4 modulation of monocyte macrophage polarization

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077012
Enrollment
Unknown
Registered
2023-10-26
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic Surgery

Interventions

Esketamine Group:after the anesthesia induction, 2mg/kg esketamine was infused in 15 minutes
Control Group:equal volume of normal saline was infused in 15minutes

Sponsors

Department of Anesthesiology in The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 18-70 years; 2. ASA: I-III; 3. Patients undergoing thoracic surgery; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1.Patients who do not agree; 2. Patients who are allergic to esketamine; 3. Patients with a history of cardiac macrovascular disease such as atherosclerosis and hypertension; 4. Patients with neurological disease and increased intracranial pressure; 5. Patients with untreated or under-treated hyperthyroidism; 6. Patients who have or have had a history of severe mental disorders; 7. Patients with glaucoma; 8. Patients with preoperative chest radiographs suggesting pulmonary infection or other significant organ disease; 9. Patients with a history of drug abuse, especially morphine abuse or long-term glucocorticoid use; 10. Patients with increased white blood cell count, elevated neutrophil ratio, or elevated calcitoninogen above the upper limit of normal on preoperative examination; 11. Patients with a change in surgical procedure or bleeding volume greater than 1000 ml or surgical time longer than 6 hours; 12. Patients who participated in other clinical trials within 3 months prior to study enrollment.

Design outcomes

Primary

MeasureTime frame
Plasma Bone Morphogenetic Protein-4;WBC count;Neutrophil count;Lymphocyte count;Monocyte count;Intraoperative blood pressure;Noggin;IL-1ß;TNF-a;IL-10;

Secondary

MeasureTime frame
visual analogue scale,VAS;

Countries

China

Contacts

Public ContactLin Yang

The Second Xiangya Hospital of Central South University

linyang@csu.edu.cn+86 138 0843 6271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026